Guidance on the use of imatinib for chronic myeloid leukaemia

National Institute for Clinical Excellence
Record ID 32003000008
Authors' objectives:

To provide guidance on the use of imatinib for chronic myeloid leukaemia.

Authors' recommendations: Guidance: 1.1 Imatinib is recommended as a treatment option for the management of Philadelphia-chromosome-positive chronic myeloid leukaemia (CML) in chronic phase in adults who are intolerant of interferon-alpha (IFN-alpha) therapy or in whom IFN-alpha is deemed to have failed to control the disease. 1.2 IFN-alpha failure is defined as either: - failure to achieve complete haematological response after 3 months of IFN-alpha treatment as monotherapy or in combination with hydroxyurea, or - failure to achieve major cytogenetic response after 1 year of IFN-alpha treatment despite haematological response. IFN-alpha intolerance is defined as the presence of documented Grade 3 non-haematological toxicity, persisting for more than 2 weeks, in a patient receiving a regimen that contains IFN-alpha. 1.3 Imatinib is recommended as an option for the treatment of adults with Philadelphia-chromosome-positive CML in accelerated phase or blast crisis provided they have not received imatinib treatment at an earlier stage.
Authors' methods: Systematic review
Project Status: Completed
Year Published: 2002
URL for published report: n/a
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Antineoplastic Agents
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Imatinib Mesylate
Organisation Name: National Institute for Clinical Excellence
Contact Address: MidCity Place, 71 High Holborn, London WC1V 6NA, UK. Tel: +44 020 7067 5800; Fax: +44 020 7067 5801
Contact Name:
Contact Email:
Copyright: <p>National Institute for Clinical Excellence (NICE)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.